Titre : Benzodiazépines

Benzodiazépines : Questions médicales fréquentes

Termes MeSH sélectionnés :

Circumcision, Female

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une dépendance aux benzodiazépines ?

Le diagnostic repose sur l'évaluation des symptômes et l'historique d'utilisation des médicaments.
Dépendance aux médicaments Benzodiazépines
#2

Quels tests sont utilisés pour évaluer l'usage des benzodiazépines ?

Des tests de dépistage de drogues et des évaluations psychologiques peuvent être utilisés.
Tests de dépistage Benzodiazépines
#3

Quels critères DSM sont utilisés pour le diagnostic ?

Les critères DSM-5 incluent l'usage excessif et les symptômes de sevrage.
Troubles liés à l'usage de substances Benzodiazépines
#4

Comment évaluer l'efficacité d'un traitement par benzodiazépines ?

L'efficacité est évaluée par la réduction des symptômes d'anxiété ou d'insomnie.
Évaluation clinique Benzodiazépines
#5

Quels signes indiquent une surdose de benzodiazépines ?

Les signes incluent confusion, somnolence excessive et difficultés respiratoires.
Syndrome de sevrage Benzodiazépines

Symptômes 5

#1

Quels sont les effets secondaires courants des benzodiazépines ?

Les effets secondaires incluent somnolence, vertiges et troubles de la mémoire.
Effets indésirables Benzodiazépines
#2

Comment reconnaître une réaction allergique aux benzodiazépines ?

Les réactions allergiques peuvent se manifester par éruptions cutanées et démangeaisons.
Réactions allergiques Benzodiazépines
#3

Quels symptômes indiquent un sevrage des benzodiazépines ?

Les symptômes de sevrage incluent anxiété, insomnie et tremblements.
Syndrome de sevrage Benzodiazépines
#4

Les benzodiazépines provoquent-elles des troubles cognitifs ?

Oui, elles peuvent entraîner des troubles de la mémoire et de la concentration.
Troubles cognitifs Benzodiazépines
#5

Quels symptômes peuvent nécessiter une consultation médicale urgente ?

Des symptômes comme confusion sévère ou difficultés respiratoires nécessitent une urgence.
Urgences médicales Benzodiazépines

Prévention 5

#1

Comment prévenir la dépendance aux benzodiazépines ?

La prévention inclut une prescription prudente et une éducation sur les risques.
Prévention de la dépendance Benzodiazépines
#2

Quels conseils donner aux patients sur l'utilisation des benzodiazépines ?

Les patients doivent être informés des risques et de l'importance de suivre les prescriptions.
Éducation des patients Benzodiazépines
#3

Comment surveiller l'utilisation des benzodiazépines ?

Les médecins doivent effectuer des suivis réguliers pour évaluer l'usage et les effets.
Suivi médical Benzodiazépines
#4

Quelles stratégies non médicamenteuses peuvent aider ?

Des techniques comme la méditation et l'exercice physique peuvent réduire l'anxiété.
Thérapies alternatives Benzodiazépines
#5

Comment sensibiliser sur les risques des benzodiazépines ?

Des campagnes d'information et des ateliers peuvent sensibiliser le public aux risques.
Sensibilisation Benzodiazépines

Traitements 5

#1

Comment traiter une dépendance aux benzodiazépines ?

Le traitement inclut une désintoxication supervisée et une thérapie comportementale.
Dépendance aux médicaments Benzodiazépines
#2

Quelles alternatives existent aux benzodiazépines pour l'anxiété ?

Les alternatives incluent les antidépresseurs et les thérapies cognitivo-comportementales.
Antidépresseurs Benzodiazépines
#3

Comment réduire progressivement l'utilisation des benzodiazépines ?

La réduction doit être progressive, sous supervision médicale pour éviter le sevrage.
Sevrage Benzodiazépines
#4

Quels médicaments peuvent aider à gérer le sevrage ?

Des médicaments comme le diazépam peuvent être utilisés pour atténuer les symptômes de sevrage.
Sevrage Benzodiazépines
#5

Quelle est la durée recommandée pour l'utilisation des benzodiazépines ?

L'utilisation est généralement recommandée pour une courte durée, souvent moins de 4 semaines.
Durée du traitement Benzodiazépines

Complications 5

#1

Quelles complications peuvent survenir avec l'usage prolongé ?

L'usage prolongé peut entraîner des troubles cognitifs et une dépendance sévère.
Complications Benzodiazépines
#2

Comment les benzodiazépines affectent-elles la santé mentale ?

Elles peuvent aggraver des troubles mentaux comme la dépression et l'anxiété.
Santé mentale Benzodiazépines
#3

Quels risques sont associés à l'association avec d'autres médicaments ?

L'association avec des opioïdes ou l'alcool augmente le risque de dépression respiratoire.
Interactions médicamenteuses Benzodiazépines
#4

Les benzodiazépines peuvent-elles provoquer des chutes chez les personnes âgées ?

Oui, elles augmentent le risque de chutes et de fractures chez les personnes âgées.
Chutes Benzodiazépines
#5

Quels effets à long terme sur la mémoire sont observés ?

L'usage prolongé peut entraîner des troubles de la mémoire et des difficultés d'apprentissage.
Troubles de la mémoire Benzodiazépines

Facteurs de risque 5

#1

Quels facteurs augmentent le risque de dépendance ?

Les antécédents de troubles mentaux et l'usage prolongé augmentent le risque de dépendance.
Facteurs de risque Benzodiazépines
#2

Comment l'âge influence-t-il l'usage des benzodiazépines ?

Les personnes âgées sont plus susceptibles de subir des effets secondaires et des complications.
Âge Benzodiazépines
#3

Quel rôle joue l'environnement social dans l'usage ?

Un environnement stressant ou un manque de soutien social peut augmenter l'usage des benzodiazépines.
Environnement social Benzodiazépines
#4

Les antécédents familiaux influencent-ils l'usage ?

Oui, des antécédents familiaux de dépendance peuvent augmenter le risque d'usage problématique.
Antécédents familiaux Benzodiazépines
#5

Comment les troubles de santé mentale affectent-ils l'usage ?

Les personnes avec des troubles de santé mentale sont plus susceptibles d'utiliser des benzodiazépines.
Troubles mentaux Benzodiazépines
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Benzodiazépines : Questions médicales les plus fréquentes", "headline": "Benzodiazépines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Benzodiazépines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-04", "dateModified": "2025-04-29", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Benzodiazépines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Benzazépines", "url": "https://questionsmedicales.fr/mesh/D001552", "about": { "@type": "MedicalCondition", "name": "Benzazépines", "code": { "@type": "MedicalCode", "code": "D001552", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Alprazolam", "alternateName": "Alprazolam", "url": "https://questionsmedicales.fr/mesh/D000525", "about": { "@type": "MedicalCondition", "name": "Alprazolam", "code": { "@type": "MedicalCode", "code": "D000525", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.030" } } }, { "@type": "MedicalWebPage", "name": "Benzodiazépinones", "alternateName": "Benzodiazepinones", "url": "https://questionsmedicales.fr/mesh/D001570", "about": { "@type": "MedicalCondition", "name": "Benzodiazépinones", "code": { "@type": "MedicalCode", "code": "D001570", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Bromazépam", "alternateName": "Bromazepam", "url": "https://questionsmedicales.fr/mesh/D001960", "about": { "@type": "MedicalCondition", "name": "Bromazépam", "code": { "@type": "MedicalCode", "code": "D001960", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.110" } } }, { "@type": "MedicalWebPage", "name": "Clonazépam", "alternateName": "Clonazepam", "url": "https://questionsmedicales.fr/mesh/D002998", "about": { "@type": "MedicalCondition", "name": "Clonazépam", "code": { "@type": "MedicalCode", "code": "D002998", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.150" } } }, { "@type": "MedicalWebPage", "name": "Dévazépide", "alternateName": "Devazepide", "url": "https://questionsmedicales.fr/mesh/D020109", "about": { "@type": "MedicalCondition", "name": "Dévazépide", "code": { "@type": "MedicalCode", "code": "D020109", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.200" } } }, { "@type": "MedicalWebPage", "name": "Diazépam", "alternateName": "Diazepam", "url": "https://questionsmedicales.fr/mesh/D003975", "about": { "@type": "MedicalCondition", "name": "Diazépam", "code": { "@type": "MedicalCode", "code": "D003975", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } }, { "@type": "MedicalWebPage", "name": "Flumazénil", "alternateName": "Flumazenil", "url": "https://questionsmedicales.fr/mesh/D005442", "about": { "@type": "MedicalCondition", "name": "Flumazénil", "code": { "@type": "MedicalCode", "code": "D005442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.305" } } }, { "@type": "MedicalWebPage", "name": "Flunitrazépam", "alternateName": "Flunitrazepam", "url": "https://questionsmedicales.fr/mesh/D005445", "about": { "@type": "MedicalCondition", "name": "Flunitrazépam", "code": { "@type": "MedicalCode", "code": "D005445", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.320" } } }, { "@type": "MedicalWebPage", "name": "Flurazépam", "alternateName": "Flurazepam", "url": "https://questionsmedicales.fr/mesh/D005479", "about": { "@type": "MedicalCondition", "name": "Flurazépam", "code": { "@type": "MedicalCode", "code": "D005479", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.348" } } }, { "@type": "MedicalWebPage", "name": "Lorazépam", "alternateName": "Lorazepam", "url": "https://questionsmedicales.fr/mesh/D008140", "about": { "@type": "MedicalCondition", "name": "Lorazépam", "code": { "@type": "MedicalCode", "code": "D008140", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.450" } } }, { "@type": "MedicalWebPage", "name": "Nitrazépam", "alternateName": "Nitrazepam", "url": "https://questionsmedicales.fr/mesh/D009567", "about": { "@type": "MedicalCondition", "name": "Nitrazépam", "code": { "@type": "MedicalCode", "code": "D009567", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.565" } } }, { "@type": "MedicalWebPage", "name": "Oxazépam", "alternateName": "Oxazepam", "url": "https://questionsmedicales.fr/mesh/D010076", "about": { "@type": "MedicalCondition", "name": "Oxazépam", "code": { "@type": "MedicalCode", "code": "D010076", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.663" } } }, { "@type": "MedicalWebPage", "name": "Pirenzépine", "alternateName": "Pirenzepine", "url": "https://questionsmedicales.fr/mesh/D010890", "about": { "@type": "MedicalCondition", "name": "Pirenzépine", "code": { "@type": "MedicalCode", "code": "D010890", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.750" } } }, { "@type": "MedicalWebPage", "name": "Prazépam", "alternateName": "Prazepam", "url": "https://questionsmedicales.fr/mesh/D011222", "about": { "@type": "MedicalCondition", "name": "Prazépam", "code": { "@type": "MedicalCode", "code": "D011222", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.784" } } }, { "@type": "MedicalWebPage", "name": "Témazépam", "alternateName": "Temazepam", "url": "https://questionsmedicales.fr/mesh/D013693", "about": { "@type": "MedicalCondition", "name": "Témazépam", "code": { "@type": "MedicalCode", "code": "D013693", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.880" } } } ] }, { "@type": "MedicalWebPage", "name": "Chlordiazépoxyde", "alternateName": "Chlordiazepoxide", "url": "https://questionsmedicales.fr/mesh/D002707", "about": { "@type": "MedicalCondition", "name": "Chlordiazépoxyde", "code": { "@type": "MedicalCode", "code": "D002707", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.150" } } }, { "@type": "MedicalWebPage", "name": "Clobazam", "alternateName": "Clobazam", "url": "https://questionsmedicales.fr/mesh/D000078306", "about": { "@type": "MedicalCondition", "name": "Clobazam", "code": { "@type": "MedicalCode", "code": "D000078306", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.165" } } }, { "@type": "MedicalWebPage", "name": "Clorazépate dipotassique", "alternateName": "Clorazepate Dipotassium", "url": "https://questionsmedicales.fr/mesh/D003009", "about": { "@type": "MedicalCondition", "name": "Clorazépate dipotassique", "code": { "@type": "MedicalCode", "code": "D003009", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.180" } } }, { "@type": "MedicalWebPage", "name": "Estazolam", "alternateName": "Estazolam", "url": "https://questionsmedicales.fr/mesh/D004949", "about": { "@type": "MedicalCondition", "name": "Estazolam", "code": { "@type": "MedicalCode", "code": "D004949", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.250" } } }, { "@type": "MedicalWebPage", "name": "Médazépam", "alternateName": "Medazepam", "url": "https://questionsmedicales.fr/mesh/D008472", "about": { "@type": "MedicalCondition", "name": "Médazépam", "code": { "@type": "MedicalCode", "code": "D008472", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.550" } } }, { "@type": "MedicalWebPage", "name": "Midazolam", "alternateName": "Midazolam", "url": "https://questionsmedicales.fr/mesh/D008874", "about": { "@type": "MedicalCondition", "name": "Midazolam", "code": { "@type": "MedicalCode", "code": "D008874", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.575" } } }, { "@type": "MedicalWebPage", "name": "Olanzapine", "alternateName": "Olanzapine", "url": "https://questionsmedicales.fr/mesh/D000077152", "about": { "@type": "MedicalCondition", "name": "Olanzapine", "code": { "@type": "MedicalCode", "code": "D000077152", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.738" } } }, { "@type": "MedicalWebPage", "name": "Triazolam", "alternateName": "Triazolam", "url": "https://questionsmedicales.fr/mesh/D014229", "about": { "@type": "MedicalCondition", "name": "Triazolam", "code": { "@type": "MedicalCode", "code": "D014229", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.900" } } } ], "about": { "@type": "MedicalCondition", "name": "Benzodiazépines", "alternateName": "Benzodiazepines", "code": { "@type": "MedicalCode", "code": "D001569", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Babette Bais", "url": "https://questionsmedicales.fr/author/Babette%20Bais", "affiliation": { "@type": "Organization", "name": "Department of Psychiatry, Erasmus University Medical Centre Rotterdam, Rotterdam, Netherlands." } }, { "@type": "Person", "name": "Steven Wright", "url": "https://questionsmedicales.fr/author/Steven%20Wright", "affiliation": { "@type": "Organization", "name": "Former medical director of the Alliance for Benzodiazepine Best Practices, Portland, OR, a nonprofit resource for physicians and patients." } }, { "@type": "Person", "name": "Christine Champion", "url": "https://questionsmedicales.fr/author/Christine%20Champion", "affiliation": { "@type": "Organization", "name": "Université Lyon 1, Lyon, France, Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France." } }, { "@type": "Person", "name": "Teddy Novais", "url": "https://questionsmedicales.fr/author/Teddy%20Novais", "affiliation": { "@type": "Organization", "name": "Université Lyon 1, Lyon, France, Service pharmaceutique, Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France, Université Claude-Bernard Lyon 1, Research on Healthcare Performance (RESHAPE), Inserm U1290, Lyon, France." } }, { "@type": "Person", "name": "Jean-Michel Dorey", "url": "https://questionsmedicales.fr/author/Jean-Michel%20Dorey", "affiliation": { "@type": "Organization", "name": "Université Lyon 1, Lyon, France, Centre Hospitalier Le Vinatier, Bron, France." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The Effects of Medical Male Circumcision on Female Partners' Sexual and Reproductive Health.", "datePublished": "2022-11-11", "url": "https://questionsmedicales.fr/article/36367636", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11904-022-00638-6" } }, { "@type": "ScholarlyArticle", "name": "The effect of female circumcision on maternal and neonatal outcomes after childbirth: a cohort study.", "datePublished": "2023-01-20", "url": "https://questionsmedicales.fr/article/36670393", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12884-022-05316-4" } }, { "@type": "ScholarlyArticle", "name": "Socio-economic disparities in female genital circumcision: finding from a case-control study in Mahabad, Iran.", "datePublished": "2022-10-07", "url": "https://questionsmedicales.fr/article/36207728", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12889-022-14247-w" } }, { "@type": "ScholarlyArticle", "name": "Opinions on integrating couple counselling and female sexual reproductive health services into Voluntary Medical Male Circumcision services in Lilongwe, Malawi.", "datePublished": "2022-09-09", "url": "https://questionsmedicales.fr/article/36083991", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0273627" } }, { "@type": "ScholarlyArticle", "name": "Does previous circumcision and wealth index influence women's attitude to discontinue the practice of female genital mutilation and cutting (FGM/C) in Ethiopia?", "datePublished": "2022-08-19", "url": "https://questionsmedicales.fr/article/35984786", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0272934" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Benzazépines", "item": "https://questionsmedicales.fr/mesh/D001552" }, { "@type": "ListItem", "position": 6, "name": "Benzodiazépines", "item": "https://questionsmedicales.fr/mesh/D001569" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Benzodiazépines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Benzodiazépines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-02", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Benzodiazépines", "description": "Comment diagnostiquer une dépendance aux benzodiazépines ?\nQuels tests sont utilisés pour évaluer l'usage des benzodiazépines ?\nQuels critères DSM sont utilisés pour le diagnostic ?\nComment évaluer l'efficacité d'un traitement par benzodiazépines ?\nQuels signes indiquent une surdose de benzodiazépines ?", "url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Circumcision,+Female#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Benzodiazépines", "description": "Quels sont les effets secondaires courants des benzodiazépines ?\nComment reconnaître une réaction allergique aux benzodiazépines ?\nQuels symptômes indiquent un sevrage des benzodiazépines ?\nLes benzodiazépines provoquent-elles des troubles cognitifs ?\nQuels symptômes peuvent nécessiter une consultation médicale urgente ?", "url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Circumcision,+Female#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Benzodiazépines", "description": "Comment prévenir la dépendance aux benzodiazépines ?\nQuels conseils donner aux patients sur l'utilisation des benzodiazépines ?\nComment surveiller l'utilisation des benzodiazépines ?\nQuelles stratégies non médicamenteuses peuvent aider ?\nComment sensibiliser sur les risques des benzodiazépines ?", "url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Circumcision,+Female#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Benzodiazépines", "description": "Comment traiter une dépendance aux benzodiazépines ?\nQuelles alternatives existent aux benzodiazépines pour l'anxiété ?\nComment réduire progressivement l'utilisation des benzodiazépines ?\nQuels médicaments peuvent aider à gérer le sevrage ?\nQuelle est la durée recommandée pour l'utilisation des benzodiazépines ?", "url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Circumcision,+Female#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Benzodiazépines", "description": "Quelles complications peuvent survenir avec l'usage prolongé ?\nComment les benzodiazépines affectent-elles la santé mentale ?\nQuels risques sont associés à l'association avec d'autres médicaments ?\nLes benzodiazépines peuvent-elles provoquer des chutes chez les personnes âgées ?\nQuels effets à long terme sur la mémoire sont observés ?", "url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Circumcision,+Female#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Benzodiazépines", "description": "Quels facteurs augmentent le risque de dépendance ?\nComment l'âge influence-t-il l'usage des benzodiazépines ?\nQuel rôle joue l'environnement social dans l'usage ?\nLes antécédents familiaux influencent-ils l'usage ?\nComment les troubles de santé mentale affectent-ils l'usage ?", "url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Circumcision,+Female#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dépendance aux benzodiazépines ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'évaluation des symptômes et l'historique d'utilisation des médicaments." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'usage des benzodiazépines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de dépistage de drogues et des évaluations psychologiques peuvent être utilisés." } }, { "@type": "Question", "name": "Quels critères DSM sont utilisés pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les critères DSM-5 incluent l'usage excessif et les symptômes de sevrage." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité d'un traitement par benzodiazépines ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par la réduction des symptômes d'anxiété ou d'insomnie." } }, { "@type": "Question", "name": "Quels signes indiquent une surdose de benzodiazépines ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent confusion, somnolence excessive et difficultés respiratoires." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants des benzodiazépines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent somnolence, vertiges et troubles de la mémoire." } }, { "@type": "Question", "name": "Comment reconnaître une réaction allergique aux benzodiazépines ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les réactions allergiques peuvent se manifester par éruptions cutanées et démangeaisons." } }, { "@type": "Question", "name": "Quels symptômes indiquent un sevrage des benzodiazépines ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes de sevrage incluent anxiété, insomnie et tremblements." } }, { "@type": "Question", "name": "Les benzodiazépines provoquent-elles des troubles cognitifs ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent entraîner des troubles de la mémoire et de la concentration." } }, { "@type": "Question", "name": "Quels symptômes peuvent nécessiter une consultation médicale urgente ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme confusion sévère ou difficultés respiratoires nécessitent une urgence." } }, { "@type": "Question", "name": "Comment prévenir la dépendance aux benzodiazépines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut une prescription prudente et une éducation sur les risques." } }, { "@type": "Question", "name": "Quels conseils donner aux patients sur l'utilisation des benzodiazépines ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les patients doivent être informés des risques et de l'importance de suivre les prescriptions." } }, { "@type": "Question", "name": "Comment surveiller l'utilisation des benzodiazépines ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les médecins doivent effectuer des suivis réguliers pour évaluer l'usage et les effets." } }, { "@type": "Question", "name": "Quelles stratégies non médicamenteuses peuvent aider ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques comme la méditation et l'exercice physique peuvent réduire l'anxiété." } }, { "@type": "Question", "name": "Comment sensibiliser sur les risques des benzodiazépines ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des campagnes d'information et des ateliers peuvent sensibiliser le public aux risques." } }, { "@type": "Question", "name": "Comment traiter une dépendance aux benzodiazépines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut une désintoxication supervisée et une thérapie comportementale." } }, { "@type": "Question", "name": "Quelles alternatives existent aux benzodiazépines pour l'anxiété ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les alternatives incluent les antidépresseurs et les thérapies cognitivo-comportementales." } }, { "@type": "Question", "name": "Comment réduire progressivement l'utilisation des benzodiazépines ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La réduction doit être progressive, sous supervision médicale pour éviter le sevrage." } }, { "@type": "Question", "name": "Quels médicaments peuvent aider à gérer le sevrage ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme le diazépam peuvent être utilisés pour atténuer les symptômes de sevrage." } }, { "@type": "Question", "name": "Quelle est la durée recommandée pour l'utilisation des benzodiazépines ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'utilisation est généralement recommandée pour une courte durée, souvent moins de 4 semaines." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'usage prolongé ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "L'usage prolongé peut entraîner des troubles cognitifs et une dépendance sévère." } }, { "@type": "Question", "name": "Comment les benzodiazépines affectent-elles la santé mentale ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent aggraver des troubles mentaux comme la dépression et l'anxiété." } }, { "@type": "Question", "name": "Quels risques sont associés à l'association avec d'autres médicaments ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "L'association avec des opioïdes ou l'alcool augmente le risque de dépression respiratoire." } }, { "@type": "Question", "name": "Les benzodiazépines peuvent-elles provoquer des chutes chez les personnes âgées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles augmentent le risque de chutes et de fractures chez les personnes âgées." } }, { "@type": "Question", "name": "Quels effets à long terme sur la mémoire sont observés ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "L'usage prolongé peut entraîner des troubles de la mémoire et des difficultés d'apprentissage." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de dépendance ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents de troubles mentaux et l'usage prolongé augmentent le risque de dépendance." } }, { "@type": "Question", "name": "Comment l'âge influence-t-il l'usage des benzodiazépines ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées sont plus susceptibles de subir des effets secondaires et des complications." } }, { "@type": "Question", "name": "Quel rôle joue l'environnement social dans l'usage ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Un environnement stressant ou un manque de soutien social peut augmenter l'usage des benzodiazépines." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils l'usage ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de dépendance peuvent augmenter le risque d'usage problématique." } }, { "@type": "Question", "name": "Comment les troubles de santé mentale affectent-ils l'usage ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes avec des troubles de santé mentale sont plus susceptibles d'utiliser des benzodiazépines." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 29/04/2025

Contenu vérifié selon les dernières recommandations médicales

Sous-catégories

24 au total
└─

Alprazolam

Alprazolam D000525 - D03.633.100.079.080.030
└─

Benzodiazépinones

Benzodiazepinones D001570 - D03.633.100.079.080.070
└─

Chlordiazépoxyde

Chlordiazepoxide D002707 - D03.633.100.079.080.150
└─

Clobazam

Clobazam D000078306 - D03.633.100.079.080.165
└─

Clorazépate dipotassique

Clorazepate Dipotassium D003009 - D03.633.100.079.080.180
└─

Estazolam

Estazolam D004949 - D03.633.100.079.080.250
└─

Médazépam

Medazepam D008472 - D03.633.100.079.080.550
└─

Midazolam

Midazolam D008874 - D03.633.100.079.080.575
└─

Olanzapine

Olanzapine D000077152 - D03.633.100.079.080.738
└─

Triazolam

Triazolam D014229 - D03.633.100.079.080.900
└─└─

Bromazépam

Bromazepam D001960 - D03.633.100.079.080.070.110
└─└─

Clonazépam

Clonazepam D002998 - D03.633.100.079.080.070.150
└─└─

Dévazépide

Devazepide D020109 - D03.633.100.079.080.070.200
└─└─

Diazépam

Diazepam D003975 - D03.633.100.079.080.070.216
└─└─

Flumazénil

Flumazenil D005442 - D03.633.100.079.080.070.305
└─└─

Flunitrazépam

Flunitrazepam D005445 - D03.633.100.079.080.070.320
└─└─

Flurazépam

Flurazepam D005479 - D03.633.100.079.080.070.348
└─└─

Lorazépam

Lorazepam D008140 - D03.633.100.079.080.070.450
└─└─

Nitrazépam

Nitrazepam D009567 - D03.633.100.079.080.070.565
└─└─

Oxazépam

Oxazepam D010076 - D03.633.100.079.080.070.663
└─└─

Pirenzépine

Pirenzepine D010890 - D03.633.100.079.080.070.750
└─└─

Prazépam

Prazepam D011222 - D03.633.100.079.080.070.784
└─└─

Témazépam

Temazepam D013693 - D03.633.100.079.080.070.880
└─└─└─

Nordazépam

Nordazepam D003708 - D03.633.100.079.080.070.216.500

Auteurs principaux

Babette Bais

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, Erasmus University Medical Centre Rotterdam, Rotterdam, Netherlands.

Steven Wright

2 publications dans cette catégorie

Affiliations :
  • Former medical director of the Alliance for Benzodiazepine Best Practices, Portland, OR, a nonprofit resource for physicians and patients.

Christine Champion

2 publications dans cette catégorie

Affiliations :
  • Université Lyon 1, Lyon, France, Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France.
Publications dans "Benzodiazépines" :

Teddy Novais

2 publications dans cette catégorie

Affiliations :
  • Université Lyon 1, Lyon, France, Service pharmaceutique, Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France, Université Claude-Bernard Lyon 1, Research on Healthcare Performance (RESHAPE), Inserm U1290, Lyon, France.
Publications dans "Benzodiazépines" :

Jean-Michel Dorey

2 publications dans cette catégorie

Affiliations :
  • Université Lyon 1, Lyon, France, Centre Hospitalier Le Vinatier, Bron, France.
Publications dans "Benzodiazépines" :

Pierre Krolak-Salmon

2 publications dans cette catégorie

Affiliations :
  • Université Lyon 1, Lyon, France, Inserm U1028, CNRS UMR5292, Centre de recherche en neurosciences de Lyon, Lyon, France, Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France, Centre Mémoire Ressource et Recherche de Lyon (CMRR), Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France.
Publications dans "Benzodiazépines" :

Alexis Lepetit

2 publications dans cette catégorie

Affiliations :
  • Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France, CNRS UMR 5229, Institut des Sciences Cognitives Marc-Jeannerod, Team "Neuroplasticity in Parkinson's disease".
Publications dans "Benzodiazépines" :

Richard Balon

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry and Behavioral Neurosciences and Anesthesiology, Wayne State University, Detroit, MI, USA. rbalon@wayne.edu.
Publications dans "Benzodiazépines" :

Vladan Starcevic

2 publications dans cette catégorie

Affiliations :
  • Discipline of Psychiatry, Nepean Clinical School, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Publications dans "Benzodiazépines" :

Md Yeunus Mian

2 publications dans cette catégorie

Affiliations :
  • Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
  • Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Dishary Sharmin

2 publications dans cette catégorie

Affiliations :
  • Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
  • Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Prithu Mondal

2 publications dans cette catégorie

Affiliations :
  • Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
  • Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Jawad Bin Belayet

2 publications dans cette catégorie

Affiliations :
  • Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
  • Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Publications dans "Benzodiazépines" :

M Mahmun Hossain

2 publications dans cette catégorie

Affiliations :
  • Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
  • Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Paul McCusker

2 publications dans cette catégorie

Affiliations :
  • Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Kaetlyn T Ryan

2 publications dans cette catégorie

Affiliations :
  • Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Alexander Y Fedorov

2 publications dans cette catégorie

Affiliations :
  • UW Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Heather A Green

2 publications dans cette catégorie

Affiliations :
  • UW Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Spencer S Ericksen

2 publications dans cette catégorie

Affiliations :
  • UW Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Mostafa Zamanian

2 publications dans cette catégorie

Affiliations :
  • Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Sources (10000 au total)

The Effects of Medical Male Circumcision on Female Partners' Sexual and Reproductive Health.

Voluntary medical male circumcision (VMMC) reduces the risk of HIV acquisition by 60% among heterosexual men, provides protection against certain sexually transmitted infections (STI), and leads to pe... Systematic reviews find strong evidence for beneficial effects of VMMC on female sex partners risk of HPV, cervical dysplasia, cervical cancer, and with likely protection against trichomoniasis and ce...

The effect of female circumcision on maternal and neonatal outcomes after childbirth: a cohort study.

Circumcision has many side effects and complications on women's lives and affects their physical, mental, and social health. The present study aimed to investigate the effect of female circumcision on... Methods: A prospective cohort study was performed with 320 pregnant women by convenience sampling (160 individuals were circumcised and 160 were uncircumcised). Circumcision and its level were confirm... The mean age of circumcised women was significantly higher vs. Uncircumcised women (28.92±6.2 vs. 25.42±4.8; P < 0.001). Circumcision was significantly higher in rural compared to urban areas (51.9% v... These findings underscore that Circumcision a prevalent predictor of poor neonatal outcomes and delivery processes, therefore this circumcised women needs intensive care during delivery....

Socio-economic disparities in female genital circumcision: finding from a case-control study in Mahabad, Iran.

Female genital circumcision (FGC) is still a challenge in reproductive health. This study investigated socioeconomic disparities in FGC in the Kurdish region of Mahabad, Iran.... A case-control study was conducted in three comprehensive health centers on 130 circumcised girls as the case group and 130 girls without a history of circumcision as the control group, according to t... Multivariate logistic regression showed that a family history of FGC (AOR 9.90; CI 95%: 5.03-19.50), age ranging between 20 and 30 years (AOR 8.55; CI 95%: 3.09-23.62), primary education (AOR 6.6; CI ... The present study provided evidence on socioeconomic factors related to FGC in girls. A family history of FGC, age ranging between 20 and 30 years, and girls' and their mothers' education level were s...

Opinions on integrating couple counselling and female sexual reproductive health services into Voluntary Medical Male Circumcision services in Lilongwe, Malawi.

Couples HIV Counselling and Testing (CHCT) has been found to be potentially beneficial than individual HIV Counselling and Testing for prevention and treatment of HIV. However, there are few health ca... We conducted a qualitative study in Lilongwe, Malawi between June to August 2018. Twenty VMMC clients, 20 peers and 20 VMMC providers completed individual in-depth interviews to share their opinions o... All participants were receptive to integration of CHCT, and most accepted the integration of SRH services into VMMC Services. Most VMMC clients, peers and care providers said that CHCT integration wou... Most participants service providers, VMMC clients and Peers were receptive to integrating SRH services, particularly HIV prevention services such as CHCT and PrEP, into male dominated VMMC services. A...

Does previous circumcision and wealth index influence women's attitude to discontinue the practice of female genital mutilation and cutting (FGM/C) in Ethiopia?

understanding women's attitudes towards female genital mutilation is an important step towards eliminating this practice. We used the 2016 Ethiopia Demographic and Health Survey (EDHS) data set to exa... Data from 6984 women aged 15-49 years were extracted from the 2016 Ethiopia EDHS data set. Multivariable logistic regression analysis was performed to analyse the data.... In this study, women with a higher level of education and wealth index were more likely to support the cessation of FGM. However, circumcised women (AOR: 0.22; 95% CI: 0.15-0.32), women from the Afar ... The present study revealed that wealth index, education level, history of circumcision, and regional variation are associated with women's attitude towards discontinuation of the practice of FGM in Et...

Longitudinal Changes in the Composition of the Penile Microbiome Are Associated With Circumcision Status, HIV and HSV-2 Status, Sexual Practices, and Female Partner Microbiome Composition.

Penile microbiome composition has been associated with HSV-2 and HIV in men and with bacterial vaginosis (BV) and HSV-2 in female sex partners. This study sought to 1) characterize penile microbiome c... This prospective study of community-recruited heterosexual couples in Kenya measured penile and vaginal microbiomes... Among 218 men with 740 observations, men had a median age of 26 years, 11.6% were living with HIV, and 46.1% were HSV-2 seropositive. We identified 7 penile community types that varied with circumcisi... Over a 1-year period, penile microbiome composition was stable for a substantial proportion of men and was influenced by men's circumcision status, sexual practices, female partner's vaginal CST and B...

Daughter circumcision and maternal life satisfaction: a cultural moderation effect revealed across two multicountry studies.

The present paper assessed the relationship between maternal life satisfaction (MLS) and the intergenerational transmission of female genital cutting (FGC, female circumcision). It was hypothesised th... Across two studies with more than 85 000 participants in 15 African and Asian countries, mothers completed surveys reporting on their own FGC experiences and those of their daughters' and on their edu... The association between MLS and daughter circumcision was weak but positive for the full sample. Contrary to predictions, in countries in which FGC is uncommon, it was more positively associated with ... Results are contrary to the notion that the intergenerational transmission of FGC is a function of happiness deriving from its cultural normativity. They suggest, instead, a diversity of social motive...